PAION AG / Key word(s): Research Update 10.10.2014 14:41 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- PAION EXPECTS ONO'S REMIMAZOLM DECISION ON FILING IN JAPAN IN NOVEMBER 2014 - Filing no longer possible in 2014 given the preparation works for filing - Filing decision will also be based on now available PK data Aachen (Germany), 10 October 2014 - PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange General Standard: PA8) today announced that its Japanese partner, ONO Pharmaceutical Co., Ltd. ("ONO") has informed PAION AG, that a decision on filing will be made in early November. Due to necessary preparations for filing and the ongoing discussions around PK issues filing will not be initiated in 2014. After unclear PK findings in an explorative dose finding Phase II trial in ICU sedation performed by ONO the trial was halted in 2013 and an intensive joint pre-clinical programme was initiated to elucidate the unexpected high plasma levels in a few patients. This joint effort now has been concluded and no explanation for the findings of high plasma levels could be identified. The studies included a 7 day study in monkeys as well as a 5 day superfusion of isolated hepatocytes. In addition the PK data of the Phase II study in cardiac surgery performed in Leipzig were integrated into the pharmacokinetic modelling. From PAION's perspective all remaining questions around the PK issue can only be answered in a new dose finding study in ICU sedation with lower doses and lighter sedation. ONO may however consider the PK data issue as a risk for filing in the indication of General Anaesthesia in Japan. This will not have any effects on PAION's ongoing development program in General Anaesthesia in Europe and Procedural Sedation in the US. ONO entered into a license agreement with PAION (formerly CeNeS) in August 2007, acquiring the exclusive right to develop and market Remimazolam in Japan. PAION had expected that ONO would file in the 2nd half of 2014. --------------------------------------------------------------------------- Information and Explaination of the Issuer to this News: About PAION PAION AG is a publicly-listed Specialty Pharma Company headquartered in Aachen, Germany with a second site in Cambridge, UK. The company has a track record in developing and out licensing of hospital-based treatments for which there is substantial unmet medical need. PAION's strategy is to extend its business model from a pure development company to a specialty pharmaceutical company with a focus on anaesthesia products. Remimazolam is intended to be the basis for its future marketing activities. Contact Ralf Penner Director Investor Relations / Public Relations PAION AG Martinstrasse 10-12 52062 Aachen - Germany Phone: +49 241 4453-152 E-mail: r.penner@paion.com www.paion.com Disclaimer: This release contains certain forward-looking statements concerning the future business of PAION AG. These forward-looking statements contained herein are based on the current expectations, estimates and projections of PAION AG's management as of the date of this release. They are subject to a number of assumptions and involve known and unknown risks, uncertainties and other factors. Should actual conditions differ from the Company's assumptions, actual results and actions may differ materially from any future results and developments expressed or implied by such forward-looking statements. Considering the risks, uncertainties and other factors involved, recipients should not rely unreasonably upon these forward-looking statements. PAION AG has no obligation to periodically update any such forward-looking statements to reflect future events or developments. 10.10.2014 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: PAION AG Martinstr. 10-12 52062 Aachen Germany Phone: +49 (0)241-4453-0 Fax: +49 (0)241-4453-100 E-mail: info@paion.com Internet: www.paion.com ISIN: DE000A0B65S3 WKN: A0B65S Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------
DGAP-Adhoc: PAION EXPECTS ONO'S REMIMAZOLM DECISION ON
Top 10 Most Recent News Articles
Alpha's Training Bet Reaches Into Aesthetic Care Networks
Training is becoming part of the operating machine A certificate course is rarely the headline-grabber in healthcare services, yet this one deserves a closer look. Alpha Aesthetics Partners has launched Practice Aesthetics, a unified clinical education platform tied directly to its expanding network of medical aesthetics practices. This is not a public-market ticker...
Continue Reading
Universal Haptics Protocol May Cut Integration Friction
A controller rumbling at the wrong moment is a small annoyance, but the plumbing behind that rumble has been a stubborn mess for years. The Haptics Industry Forum's Universal Haptics Protocol 1.0, announced November 17, 2026, is an attempt to clean up that mess with a shared language between software and touch-feedback hardware. This is not the sort of release that sends...
Continue Reading
Paratus on the Move: Seagems JV Under the Microscope
What's Cooking with Paratus Energy? Paratus Energy Services Ltd. (ticker: PLSV) just threw us a curveball, announcing a strategic review of its participation in the Seagems joint venture. Now, before you get too jazzed about ticker talk—hold your horses. No one's making any promises about transactions just yet. The decision's still hanging in the balance, even as they...
Continue Reading
Philadelphia Firm Targets 100 Toys for Children This Holiday
A hundred unopened toys can look modest on paper, yet that is exactly why this Philadelphia effort lands differently than the usual chest-thumping corporate charity chatter. van der Veen, Hartshorn & Levin has set a clear holiday target: collect 100 new, unwrapped toys for children in the Philadelphia area through the U.S. Marine Corps Reserve Toys for Tots program. No...
Continue Reading
Unishippers Climbs 18 Slots on 32.4% Sales Growth Run
Thirty new franchise units can move the needle fast Unishippers did not inch its way up the Franchise Times Top 400; it put up a number that deserves a hard look. Sales rose 32.4% in 2025, the company added 30 franchise units, and the result was an 18-place jump to No. 81 on the 2026 ranking. In the shipping category, it was named the sales-growth leader. For a business...
Continue Reading
Knotch Bets Brands Need Answers, Not More Web Pages
Pages are starting to look like expensive filing cabinets A website that cannot answer an agent may soon be expensive wallpaper. That is the blunt premise behind Knotch's Ace for Agents, launched Nov. 17, 2026, and frankly it lands because plenty of big companies have spent years piling pages atop pages until nobody can tell which claim is current. Knotch is pitching an...
Continue Reading
Apani Adds Kelsun Assets to Its Natural Fiber Platform
A materials deal with more chemistry than chest-thumping Seaweed and cotton have landed under one roof, which is a lot more interesting than another apparel brand slapping a green label on ordinary fabric. Apani said November 17 it acquired the assets of Keel Labs, bringing Keel's seaweed-based Kelsun fiber alongside Apani's enhanced cotton-cellulose filament technology....
Continue Reading
Medical School Rejections Carry a Steep Price Tag Too
A rejection letter can turn into a remarkably expensive piece of paper. BeMo Academic Consulting's new Medical School Admissions Trends Report argues that the damage from missing medical-school admission goes far beyond bruised confidence: applicants can spend thousands chasing another cycle, lose time entering practice, and, if they never get in, forgo what the report...
Continue Reading
Historic China-Russia-US Summit Aims for Global Stability
The Weight of History in Shenzhen When the big players decide to talk face-to-face, it's more than just a photo op. This week in Shenzhen, the leaders of China, Russia, and the United States are doing just that. And let me tell you, it's the kind of gathering that can either stabilize the gears of global politics or grease the wheels of tension. This chinwag isn't just...
Continue Reading
A Decade of Giving: Light the World Initiative's Impact
The Red Kiosk Revolution It's not every day that a church initiative pops up in global conversations, but here we are—ten years into the Light the World initiative by The Church of Jesus Christ of Latter-day Saints. What's interesting is how these little kiosks, like silent ambassadors, have become a staple in 145 spots this holiday season, spanning continents. Each...
Continue ReadingTop 5 Most Recently Viewed Articles
Furniture.com Launches $1,500 Giveaway for Back-to-School Fun
Exciting Giveaway from Furniture.com Just in Time for School The online marketplace, Furniture.com, is inviting new social media followers to participate in an exciting giveaway allowing one lucky winner to receive a $1,500 gift card. This giveaway is perfect for anyone looking to enhance their living spaces, such as dorms, home offices, or children's rooms. Transforming...
Continue Reading
Kraken Robotics Achieves Unprecedented Growth in Q3 2025
Kraken Robotics Inc. Reports Stellar Q3 2025 Results Kraken Robotics Inc. (TSXV: PNG, OTCQB: KRKNF) has recently released its financial results for Q3 2025, showcasing a remarkable growth trajectory. The company reported consolidated revenue of $31.3 million, marking a significant 60% increase from $19.6 million in the same quarter last year. This surge in revenue can be...
Continue Reading
NVIDIA Innovates AI for Robotics and Autonomous Solutions
NVIDIA Enhances Robotics and Automation with New AI Models NVIDIA Corp (NASDAQ: NVDA) is making waves in the semiconductor landscape with its latest advancements in artificial intelligence (AI). With a staggering revenue exceeding $113 billion, NVIDIA has announced innovative generative AI models aimed at improving its Omniverse platform. This initiative is focused on...
Continue Reading
Takeda's ENTYVIO: Transforming IBD Treatment and Market Growth
ENTYVIO's Impact on IBD Treatment Takeda Pharmaceutical continues to enhance patient care with ENTYVIO, a gut-selective biologic designed specifically for inflammatory bowel disease (IBD) management. With the recent introduction of a subcutaneous formulation, ENTYVIO has improved patient convenience, allowing for easier administration at home. This evolution in treatment...
Continue Reading
Join AM Best's Complimentary Webinar on AI Litigation Strategies
AM Best Webinar Overview AM Best, a global leader in insurance credit ratings, is excited to announce a complementary webinar titled “Defending Artificial Intelligence Claims.” This informative session aims to delve into the intricate world of AI-related legal challenges. Key Discussion Points The webinar will take place at 2:00 p.m. (EST) and features a panel of...
Continue Reading